arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Aardvark Therapeutics, Inc.

AARD

$7.80 ▲ +0.47 (+6.41%) at close

10 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Aardvark Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $170.2M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -20.4% ↘

FCF / Share $-0.86

Trailing P/E —

Price / Book 2.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-21.59M

↓ -131.9% —

FCF / Share Free cash flow per share

$-0.86

— -0.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
EPS Growth YoY (%)	-39.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	62.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	28.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	51.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-29.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-131.9% Weak ↑ Weak Improving Year-over-year change in net income	-100.5% Weak ↑ Weak Improving Year-over-year change in net income	-290.1% Weak ↓ Weak Declining Year-over-year change in net income	-163.7% Weak Weak Year-over-year change in net income	-327.5% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	-0.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	—	25.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	57.8% Excellent Excellent Year-over-year change in free cash flow	-56.0% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
FCF / Net Income (x)	0.87x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.22x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Return on Invested Capital (%)	-20.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	13.7% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	8.7% Fair ↑ Fair Improving Return earned on debt + equity capital invested Optimal: > 10%	11.3% Good Good Return earned on debt + equity capital invested Optimal: > 10%	4.6% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-22.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-13.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-6.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-12.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-24.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-265%)	-16.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-210%)	-13.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-189%)	-10.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-170%)	-6.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-141%)	16.1% Good ↑ Good Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+7%)	9.1% Caution → Caution Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-40%)	12.9% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-14%)	5.9% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-61%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Net Debt (USD)	$-62.44M	$-47.05M	$-39.28M	$-26.00M	$-26.50M	$-61.64M	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Revenue per Share (USD)	$0.00	—	—	—	$0.00	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.99	$-0.81	$-0.75	$-0.66	$-0.71	$-2.18	$-1.05	$-1.37	$-0.55	—
Free Cash Flow per Share (USD)	$-0.86	—	$-0.74	$-0.46	$-0.86	—	$-0.99	$-1.09	$-0.55	—
Book Value per Share (USD)	$3.99	$4.89	$5.63	$6.31	$6.95	$-13.44	$-11.58	$-10.66	$-9.30	—
Tangible Book Value per Share (USD)	$3.99	$4.89	$5.63	$6.31	$6.95	$-13.44	$-11.58	$-10.66	$-9.30	—
Basic Weighted Avg Shares (shares)	21.82M	—	21.71M	21.69M	13.19M	—	3.99M	3.97M	3.97M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Working Capital (USD)	$81.98M	$101.34M	$118.47M	$134.46M	$148.58M	$69.21M	—	—	—	—
Total Equity (USD)	$86.99M	$106.63M	$122.38M	$136.93M	$150.69M	$-54.64M	$-46.17M	$-42.31M	$-36.91M	$-34.80M

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	—	—	—	$0.00	—	—	—	—	—
Depreciation Expense (USD)	$11.00K	$10.00K	$10.00K	$11.00K	$5.00K	$8.00K	$8.00K	$-2.00K	$2.00K	—
Net Income, GAAP (USD)	$-21.59M	$-17.60M	$-16.32M	$-14.37M	$-9.31M	$-8.78M	$-4.18M	$-5.45M	$-2.18M	—
Operating Cash Flow (USD)	$-18.87M	$-16.81M	$-16.13M	$-9.84M	$-11.39M	$-7.73M	$-3.96M	$-4.21M	$-2.19M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 10 quarters

Aardvark Therapeutics, Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare AARD with peers